High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing.
暂无分享,去创建一个
Jun Wang | Yanan Guo | Fan Yang | Yanan Du | Yanan Du | Jun Wang | Fan Yang | Xiaojun Yan | Xiaojun Yan | Xun Wang | Lyu Zhou | Zhaozhao Wu | Xun Wang | Xiuyuan Chen | Min Wu | Yuyang Chen | Wenjing Li | Wenjing Li | Min Wu | Lyu Zhou | Yuyang Chen | Xiuyu Chen | Zhaozhao Wu | Yangqiang Guo
[1] Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications , 2018, Nature Reviews Drug Discovery.
[2] N. Kotov,et al. Three-dimensional cell culture matrices: state of the art. , 2008, Tissue engineering. Part B, Reviews.
[3] L. Kraus-Berthier,et al. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] F. Colpaert,et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid , 1998, Cancer Chemotherapy and Pharmacology.
[5] D. Grainger,et al. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. , 2012, Pharmacology & therapeutics.
[6] Ming-Rong Zhang,et al. High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment. , 2015, Biomaterials.
[7] Denis Wirtz,et al. Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.
[8] C. Verbeke,et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing , 2013, BMC Cancer.
[9] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[10] Robert M. Plenge,et al. Disciplined approach to drug discovery and early development , 2016, Science Translational Medicine.
[11] Andrew L. Kung,et al. Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.
[12] Shuichi Takayama,et al. 384 hanging drop arrays give excellent Z‐factors and allow versatile formation of co‐culture spheroids , 2012, Biotechnology and bioengineering.
[13] C. Lovitt,et al. Miniaturized three-dimensional cancer model for drug evaluation. , 2013, Assay and drug development technologies.
[14] M. Spector,et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.
[15] A. Napper,et al. Beta-hairpin hydrogels as scaffolds for high-throughput drug discovery in three-dimensional cell culture. , 2017, Analytical biochemistry.
[16] Serena M Best,et al. Investigating the morphological, mechanical and degradation properties of scaffolds comprising collagen, gelatin and elastin for use in soft tissue engineering. , 2012, Journal of the mechanical behavior of biomedical materials.
[17] J. Takagi,et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. , 2018, Cell stem cell.
[18] R. Jain,et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.
[19] Hans Clevers,et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.
[20] G. Viglietto,et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib , 2006, Journal of cellular physiology.
[21] G. Xiong,et al. Function of cancer cell-derived extracellular matrix in tumor progression , 2016 .
[22] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[23] B. Cho,et al. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. , 2016, Lung cancer.
[24] Moo-Yeal Lee,et al. Biocompatible Hydrogels for Microarray Cell Printing and Encapsulation , 2015, Biosensors.
[25] Yinzhi Lai,et al. Three-dimensional polymer scaffolds for high throughput cell-based assay systems. , 2008, Biomaterials.
[26] Daniel J. Maltman,et al. Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. , 2010, Biochemical Society transactions.
[27] Y. Kodera,et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis , 2006, British Journal of Cancer.
[28] P. Netti,et al. 3D is not enough: Building up a cell instructive microenvironment for tumoral stroma microtissues. , 2017, Acta biomaterialia.
[29] Liju Yang,et al. Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins , 2016, PloS one.
[30] M. Raghunath,et al. Electro-spinning of pure collagen nano-fibres - just an expensive way to make gelatin? , 2008, Biomaterials.
[31] David Sidransky,et al. Patient-derived xenografts for individualized care in advanced sarcoma , 2014, Cancer.
[32] M. Ferrer,et al. Three-Dimensional Cell Culture Assays: Are They More Predictive of In Vivo Efficacy than 2D Monolayer Cell-Based Assays? , 2015, Assay and drug development technologies.
[33] D. H. Randle,et al. Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening? , 2015, Assay and drug development technologies.
[34] Bon-Kyoung Koo,et al. Human Primary Liver Cancer -derived Organoid Cultures for disease modelling and drug screening , 2017, Nature Medicine.
[35] Yunjung Choi,et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. , 2009, Lung cancer.
[36] F. Gasparri,et al. The development of high-content screening (HCS) technology and its importance to drug discovery , 2016, Expert opinion on drug discovery.
[37] G. Peters,et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.
[38] Yanan Du,et al. Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment. , 2014, Lab on a chip.
[39] Yasunosuke Suzuki,et al. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. , 2005, International journal of hygiene and environmental health.
[40] L. O’Driscoll,et al. Three-dimensional cell culture: the missing link in drug discovery. , 2013, Drug discovery today.
[41] John W Haycock,et al. 3D cell culture: a review of current approaches and techniques. , 2011, Methods in molecular biology.
[42] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[43] A. IJzerman,et al. Label-free technology and patient cells: from early drug development to precision medicine. , 2017, Drug discovery today.
[44] B. Thierry,et al. Quasi-spherical microwells on superhydrophobic substrates for long term culture of multicellular spheroids and high throughput assays. , 2014, Biomaterials.
[45] A. Corti,et al. Improving drug penetration to curb tumor drug resistance. , 2012, Drug discovery today.
[46] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[47] M. Vincenti,et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. , 2002, Urologic oncology.
[48] A. Villanueva,et al. The future of patient-derived tumor xenografts in cancer treatment. , 2015, Pharmacogenomics.
[49] Liju Yang,et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. , 2014, Assay and drug development technologies.
[50] Stefania Forti,et al. New insights into the role of extracellular matrix during tumor onset and progression , 2002, Journal of cellular physiology.
[51] F. Ciardiello,et al. Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition , 2014, Clinical Cancer Research.
[52] Anne E Carpenter,et al. Increasing the Content of High-Content Screening , 2014, Journal of biomolecular screening.
[53] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[54] Roland Eils,et al. Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations , 2017, Molecular systems biology.
[55] C. Takimoto. Anticancer drug development at the US National Cancer Institute , 2003, Cancer Chemotherapy and Pharmacology.
[56] M. Campiglio,et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling , 2008, Breast Cancer Research and Treatment.
[57] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[58] 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response , 2016, BMC Cancer.
[59] Yang Zeng,et al. Biomechanically primed liver microtumor array as a high-throughput mechanopharmacological screening platform for stroma-reprogrammed combinatorial therapy. , 2017, Biomaterials.
[60] Deepti Singh,et al. Synthesis of composite gelatin-hyaluronic acid-alginate porous scaffold and evaluation for in vitro stem cell growth and in vivo tissue integration. , 2014, Colloids and surfaces. B, Biointerfaces.
[61] R L Reis,et al. A novel hanging spherical drop system for the generation of cellular spheroids and high throughput combinatorial drug screening. , 2015, Biomaterials science.
[62] Sridhar Ramaswamy,et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.
[63] M. López-Caballero,et al. Functional and bioactive properties of collagen and gelatin from alternative sources: A review , 2011 .
[64] Elias A. Rivera,et al. Cross‐linked gelatin microspheres with continuously tunable degradation profiles for renal tissue regeneration , 2014, Biotechnology and applied biochemistry.
[65] Frank McCormick,et al. AKT inactivation causes persistent drug tolerance to EGFR inhibitors. , 2015, Pharmacological research.
[66] S. Sant,et al. The production of 3D tumor spheroids for cancer drug discovery. , 2017, Drug discovery today. Technologies.
[67] A. Nowak,et al. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice , 2017, BMC Cancer.
[68] Jenny C. Chang,et al. Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.